Products
To learn more about our products please choose a therapeutic area and download the Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs). This information is intended only for UK residents.
CNS
Arlevert®
Arlevert (cinnarizine 20mg, dimenhydrinate 40mg) was developed by Hennig Arzneimittel GmbH & Co of Germany. Hampton has exclusive rights to Arlevert in the UK where it is indicated for the treatment of vertigo symptoms of various origins.
Arlevert PIL.pdf
Arlevert SmPC.pdf
 |
| Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported to Hampton Pharmaceuticals on medical@hamptonpharma.co.uk or 01923 204322 |
